Fairmont Hotel Vancouver Floorplan
This meeting took place in 2022
Here are the related meetings in 2024:
Ubiquitin Biology and Disease (J6)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Ubiquitin Biology - RESCHEDULED (RJ5)
Organizer(s) Eric J. Bennett, Nicolas H. Thomä and Niels Mailand
November 6—9, 2022
Fairmont Hotel Vancouver • Vancouver, BC Canada
Abstract Deadline: Sep 19, 2022
Scholarship Deadline: Nov 26, 2021
Discounted Registration Deadline: Sep 6, 2022
Sponsored by Astellas Pharma Inc. and Genentech, Inc.
Joint Meeting:
Targeted Protein Degradation - RESCHEDULED (RJ6)
Summary of Meeting:
Protein ubiquitylation regulates nearly every critical cellular pathway and emerging evidence has demonstrated that defects within the ubiquitin proteasome system can directly lead human disease, most notably neurodegenerative disorders. This has fueled a recent expansion of drug development efforts to harness the ubiquitin proteasome system to both aid in its functionality during disease progression and to specify individual targets for degradation. Several key questions regarding ubiquitin biology remain unanswered. Can individual cellular pathways, like DNA repair, be specifically manipulated by altering the activity of ubiquitin pathway enzymes? What are the major factors that limit ubiquitin proteasome function during disease pathogenesis? How do infectious diseases impact the ubiquitin system, and can we utilize these diverse mechanisms to develop new tools and paradigms to manipulate the ubiquitin system? The specific goals of the proposed meeting are: 1- Establish detailed connections between the diverse cellular pathways regulated by the ubiquitin system. 2- Determine the structural rules defining how individual proteins are specifically targeted by ubiquitin pathway enzymes. 3- Identify emerging themes using by pathogens to subvert the ubiquitin system 4- Foster enhanced collaboration between academia and the biotechnology industry toward the goal of developing therapeutics targeting the ubiquitin system. This joint meeting with “Targeted Protein Degradation” will provide a cross-disciplinary understanding of the various genetic and chemical approaches to identify mechanisms to specifically target individual proteins for degradation. One key outcome will be the establishment of collaborations between ubiquitin biologists studying how individual pathways are regulated by ubiquitin and industry leaders developing tools to both activate and inhibit ubiquitin pathway components.
View Scholarships/Awards
Protein ubiquitylation regulates nearly every critical cellular pathway and emerging evidence has demonstrated that defects within the ubiquitin proteasome system can directly lead human disease, most notably neurodegenerative disorders. This has fueled a recent expansion of drug development efforts to harness the ubiquitin proteasome system to both aid in its functionality during disease progression and to specify individual targets for degradation. Several key questions regarding ubiquitin biology remain unanswered. Can individual cellular pathways, like DNA repair, be specifically manipulated by altering the activity of ubiquitin pathway enzymes? What are the major factors that limit ubiquitin proteasome function during disease pathogenesis? How do infectious diseases impact the ubiquitin system, and can we utilize these diverse mechanisms to develop new tools and paradigms to manipulate the ubiquitin system? The specific goals of the proposed meeting are: 1- Establish detailed connections between the diverse cellular pathways regulated by the ubiquitin system. 2- Determine the structural rules defining how individual proteins are specifically targeted by ubiquitin pathway enzymes. 3- Identify emerging themes using by pathogens to subvert the ubiquitin system 4- Foster enhanced collaboration between academia and the biotechnology industry toward the goal of developing therapeutics targeting the ubiquitin system. This joint meeting with “Targeted Protein Degradation” will provide a cross-disciplinary understanding of the various genetic and chemical approaches to identify mechanisms to specifically target individual proteins for degradation. One key outcome will be the establishment of collaborations between ubiquitin biologists studying how individual pathways are regulated by ubiquitin and industry leaders developing tools to both activate and inhibit ubiquitin pathway components.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, November 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, November 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, November 10 in order to fully experience the meeting.
SUNDAY, NOVEMBER 6
MONDAY, NOVEMBER 7
TUESDAY, NOVEMBER 8
WEDNESDAY, NOVEMBER 9
THURSDAY, NOVEMBER 10
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, November 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, November 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, November 10 in order to fully experience the meeting.
SUNDAY, NOVEMBER 6
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Eric J. Bennett,
University of California, San Diego, USA
Session Chair
Session Chair
Ivan Dikic,
Goethe University Medical School, Germany
Ubiquitination and Remodeling of Organelles
Ubiquitination and Remodeling of Organelles
08:00—09:00
Welcome and Keynote Address
*
Rajesh Chopra,
Apple Tree Partners, USA
Benjamin L. Ebert,
Dana-Farber Cancer Institute, USA
Targeted Protein Degradation for the Treatment of Cancer
Targeted Protein Degradation for the Treatment of Cancer
09:00—11:30
Regulating Nuclear Function with Ubiquitin
*
Achim Werner,
NIDCR, National Institutes of Health, USA
Goran Kokic,
Max Planck Institute for Biophysical Chemistry, Germany
Transcription-coupled DNA Repair: Lessons Learned on the Ubiquitylation of Complex Substrates
Transcription-coupled DNA Repair: Lessons Learned on the Ubiquitylation of Complex Substrates
Coffee Break
Jo R. Morris,
University of Birmingham, UK
SUMOylation in the DNA Double-Strand Break Response
SUMOylation in the DNA Double-Strand Break Response
Niels Mailand,
University of Copenhagen, Denmark
Ubiquitin-Dependent Signaling in the DNA Damage Response
Ubiquitin-Dependent Signaling in the DNA Damage Response
Stefan Müller,
Goethe-University Frankfurt, Germany
Short Talk: Safeguarding Proteome and Genome Integrity by Sumo-ubiquitin Networks
Short Talk: Safeguarding Proteome and Genome Integrity by Sumo-ubiquitin Networks
Imke Leonie Lemmer,
LMU Munich, Germany
Short Talk: Nfe2l1 Shapes the Muscle Ubiquitome to Regulate Fiber Type and Metabolic Fitness
Short Talk: Nfe2l1 Shapes the Muscle Ubiquitome to Regulate Fiber Type and Metabolic Fitness
09:00—11:15
Proteolysis Targeting Chimeras (PROTACs)
Alessio Ciulli,
University of Dundee, School of Life Sciences, UK
Structural Chemical Biology and Insights into PROTAC Mechanism of Action
Structural Chemical Biology and Insights into PROTAC Mechanism of Action
Coffee Break
*
Nathanael Gray,
Stanford University, USA
Targeting Kinases Via Protein Degradation
Targeting Kinases Via Protein Degradation
Shaomeng Wang,
University of Michigan, USA
Targeting Transcriptional Factor STAT3 and Other STAT Proteins by PROTAC
Targeting Transcriptional Factor STAT3 and Other STAT Proteins by PROTAC
Bikash Adhikari,
University of Wuerzburg, Germany
Short Talk: Targeted Protein Degradation of Oncogenic Proteins using PROTACs
Short Talk: Targeted Protein Degradation of Oncogenic Proteins using PROTACs
Charlotte Crowe,
University of Dundee, UK
Short Talk: Novel Biophysical Assays for Small-Molecule Mediated Ternary Complex Formation and Ubiquitination
Short Talk: Novel Biophysical Assays for Small-Molecule Mediated Ternary Complex Formation and Ubiquitination
15:00—16:30
Career Roundtable (Joint)
Ivan Dikic,
Goethe University Medical School, Germany
Benjamin L. Ebert,
Dana-Farber Cancer Institute, USA
Sonya Neal,
University of California, San Diego, USA
Eva d'Hennezel,
Novartis Institutes of Biomedical Research, USA
17:00—19:00
Mechanisms of Protein Ubiquitylation and Degradation (Joint)
*
Ingrid E. Wertz,
Lyterian Therapeutics, USA
Session Chair
Session Chair
Brenda A. Schulman,
Max Planck Institute of Biochemistry, Germany
Cullin-RING E3 Ligation Mechanisms
Cullin-RING E3 Ligation Mechanisms
Weaam Ibrahim Mohamed,
Institute of Biochemistry, Switzerland
Short Talk: Regulation of RING E3 Ubiquitin Ligases by Oligomerization: What do we Learn from CRL4(DCAF1) and the hGID Complexes?
Short Talk: Regulation of RING E3 Ubiquitin Ligases by Oligomerization: What do we Learn from CRL4(DCAF1) and the hGID Complexes?
Kylie J. Walters,
NCI, National Institutes of Health, USA
Proteasome Substrate Receptor hRpn13 as an Anti-Cancer Target
Proteasome Substrate Receptor hRpn13 as an Anti-Cancer Target
Nicolas H. Thomä,
Friedrich Miescher Institute for Biomedical Research, Switzerland
The Zinc Finger Degrome
The Zinc Finger Degrome
Hadir Marei,
Genentech, Roche, USA
Short Talk: Leveraging E3 Ubiquitin Ligases as Cell Surface Protein Degraders
Short Talk: Leveraging E3 Ubiquitin Ligases as Cell Surface Protein Degraders
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Strategies for Therapeutic Targeting of the Ubiquitin Proteasome System (Joint)
*
Brenda A. Schulman,
Max Planck Institute of Biochemistry, Germany
Session Chair
Session Chair
Sara Buhrlage,
Dana-Farber Cancer Institute, USA
Approaches to Identify New DUB Inhibitors
Approaches to Identify New DUB Inhibitors
Coffee Break
Eva d'Hennezel,
Novartis Institutes of Biomedical Research, USA
Discovery and Characterization of a First-in-class Selective IKZF2 Glue Degrader for Immuno-oncology Applications
Discovery and Characterization of a First-in-class Selective IKZF2 Glue Degrader for Immuno-oncology Applications
Ingrid E. Wertz,
Lyterian Therapeutics, USA
Identification, Development, and Characterization of Inhibitors for Deubiquitinating Enzymes
Identification, Development, and Characterization of Inhibitors for Deubiquitinating Enzymes
Mandeep Kaur Mann,
University of Toronto, Canada
Short Talk: Discovery of First-in-class USP5 Inhibitors
Short Talk: Discovery of First-in-class USP5 Inhibitors
Jonathan Michael Tsai,
Harvard Medical School, USA
Short Talk: UBR5 Forms Ligand-Dependent Complexes on Chromatin to Regulate Nuclear Hormone Receptor Stability
Short Talk: UBR5 Forms Ligand-Dependent Complexes on Chromatin to Regulate Nuclear Hormone Receptor Stability
14:30—16:30
Workshop: Emerging Themes in Ubiquitin Biology
*
Eric J. Bennett,
University of California, San Diego, USA
Session Chair
Session Chair
Thang V. Nguyen,
University of Missouri, School of Medicine, USA
Suppressing the Action of Molecular Glues and PROTACs by the Deubiquitylating Enzyme USP15
Suppressing the Action of Molecular Glues and PROTACs by the Deubiquitylating Enzyme USP15
Darren M. O'Hara,
Almac Discovery, UK
Discovery of a Novel USP19 Inhibitor with Muscle Sparing Activity in vivo
Discovery of a Novel USP19 Inhibitor with Muscle Sparing Activity in vivo
Jason Q. Tang,
University of Toronto, Canada
Expanding the Druggable Space for USPs by Targeting Accessory Domains
Expanding the Druggable Space for USPs by Targeting Accessory Domains
Sammy Villa,
University of California, USA
The OTUD6 Deubiquitinase Associates with the 40S Ribosome to Regulate Translation and the Response to Stressors in Drosophila
The OTUD6 Deubiquitinase Associates with the 40S Ribosome to Regulate Translation and the Response to Stressors in Drosophila
Alexa Nadine Wilson,
Dalhousie University, Canada
Stressed Out: How a Herpesvirus E3 Ubiquitin Ligase Targets the Cellular Stress Response
Stressed Out: How a Herpesvirus E3 Ubiquitin Ligase Targets the Cellular Stress Response
Avraham Ashkenazi,
Tel Aviv University, Israel
Regulation of the Ubiquitin-activating Enzyme UBA6 by Polyalanine Tracts in Health and Disease
Regulation of the Ubiquitin-activating Enzyme UBA6 by Polyalanine Tracts in Health and Disease
Kevin Mark,
University of California, Berkeley, USA
Ubiquitin-Dependent Control of Network Dynamics Shapes Gene Expression and Cell Identity
Ubiquitin-Dependent Control of Network Dynamics Shapes Gene Expression and Cell Identity
Elijah Mena,
Brigham and Women's Hospital, USA
Mapping E3-substrate Interactions through Multiplex CRISPR Screening
Mapping E3-substrate Interactions through Multiplex CRISPR Screening
17:00—19:00
Ubiquitin-Dependent Quality Control Mechanisms
*
Mikko Taipale,
University of Toronto, Canada
Eric J. Bennett,
University of California, San Diego, USA
Ribosome Associated Quality Control Mechanisms
Ribosome Associated Quality Control Mechanisms
Miguel A. Prado,
Harvard Medical School - USA & ISPA-FINBA, Spain
Short Talk: Global Remodeling of the Proteome in Terminal Differentiation
Short Talk: Global Remodeling of the Proteome in Terminal Differentiation
Sonya Neal,
University of California, San Diego, USA
Derlins Employ a Chaperone-like Function for Resolving Misfolded Membrane Protein Stress
Derlins Employ a Chaperone-like Function for Resolving Misfolded Membrane Protein Stress
Olivia Rissland,
University of Colorado School of Medicine, USA
Short Talk: Clearance of Maternal Proteins during Early Embryogenesis
Short Talk: Clearance of Maternal Proteins during Early Embryogenesis
17:00—19:00
Novel Approaches to Protein Degradation/Homeostasis for Therapeutics
*
Eric S. Fischer,
Dana-Farber Cancer Institute, USA
How Structural Biology will Transform Targeted Protein Degradation?
How Structural Biology will Transform Targeted Protein Degradation?
Hannah B L Jones,
University of Oxford, UK
Cell Based High-throughput Screening of DUB Inhibitors using Activity-based Probe Profiling (ABPP-HT)
Cell Based High-throughput Screening of DUB Inhibitors using Activity-based Probe Profiling (ABPP-HT)
Erika Maria Lopez-Alfonzo,
University of California, Berkeley, USA
Mechanistic Dissection of Functional Asymmetries in the Proteasomal AAA+ Motor Using smFRET
Mechanistic Dissection of Functional Asymmetries in the Proteasomal AAA+ Motor Using smFRET
Pranam Chatterjee,
Duke University, USA
Short Talk: Design of Peptide-Guided Protein Degraders via Contrastive Deep Learning
Short Talk: Design of Peptide-Guided Protein Degraders via Contrastive Deep Learning
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
New Paradigms in Protein Ubiquitylation
*
Susan Shao,
Harvard Medical School, USA
Session Chair
Session Chair
Satpal Virdee,
University of Dundee, UK
Non-lysine Ubiquitination and Deubiquitination
Non-lysine Ubiquitination and Deubiquitination
Joshua L. Andersen,
Brigham Young University, USA
Short Talk: TNK1 is a Ubiquitin-sensing Kinase that can be Targeted to Block Tumor Growth
Short Talk: TNK1 is a Ubiquitin-sensing Kinase that can be Targeted to Block Tumor Growth
Luis Gerardo Villa-Diaz,
Oakland University, USA
Short Talk: Enhanced Ubiquitin Pathway Regulation in Human Pluripotent Stem Cells Cultured in Microgravity Conditions
Short Talk: Enhanced Ubiquitin Pathway Regulation in Human Pluripotent Stem Cells Cultured in Microgravity Conditions
Coffee Break
Heran Darwin,
New York University School of Medicine, USA
Regulating Pup-dependent Degradation: Work in Progress
Regulating Pup-dependent Degradation: Work in Progress
Emily Troemel,
University of California, San Diego, USA
Ubiquitin Signaling within the Intracellular Pathogen Response Pathway
Ubiquitin Signaling within the Intracellular Pathogen Response Pathway
08:00—11:00
Novel Approaches to the Development and Discovery of Molecular Glues
*
Anita K. Gandhi,
Bristol-Myers Squibb, USA
Emerging CELMoDs in Hematological Malignancies
Emerging CELMoDs in Hematological Malignancies
Georg E. Winter,
CeMM Research Center for Molecular Medicine, Austria
Chemical Genomics Approaches to Targeted Protein Degradation
Chemical Genomics Approaches to Targeted Protein Degradation
Coffee Break
Ekaterina Vinogradova,
Rockefeller University, USA
Covalent Small-Molecule Protein Degraders
Covalent Small-Molecule Protein Degraders
Zuzanna Kozicka,
Friedrich Miescher Institute for Biomedical Research, Switzerland
Short Talk: Molecular Glue Degraders of Cyclin K and the Emerging Rules for Molecular Glue Design
Short Talk: Molecular Glue Degraders of Cyclin K and the Emerging Rules for Molecular Glue Design
Carles Galdeano,
University of Barcelona, Spain
Short Talk: Expanding the Toolbox of E3 Ligases with Structure-based Approaches
Short Talk: Expanding the Toolbox of E3 Ligases with Structure-based Approaches
17:00—18:45
Ubiquitin System Dysregulation in Disease
*
Sonya Neal,
University of California, San Diego, USA
Session Chair
Session Chair
Achim Werner,
NIDCR, National Institutes of Health, USA
Dissecting Ubiquitin-dependent Cell-fate Decisions through Human Diseases
Dissecting Ubiquitin-dependent Cell-fate Decisions through Human Diseases
Lu Barnsby-Greer,
University of Dundee, UK
Short Talk: An Atypical E3 Ligase Module in UBR4 Mediates Destabilization of N-degron Substrates
Short Talk: An Atypical E3 Ligase Module in UBR4 Mediates Destabilization of N-degron Substrates
Judith Dönig,
Goethe University Frankfurt, University Hospital, Germany
Short Talk: Characterization of Nucleolar SUMO Isopeptidases Unveils a p53-independent Checkpoint of Impaired Ribosome Biogenesis
Short Talk: Characterization of Nucleolar SUMO Isopeptidases Unveils a p53-independent Checkpoint of Impaired Ribosome Biogenesis
Varvara Folimonova,
NIH, USA
Short Talk: Structural Studies and Optimization of CAR Hinge Regions
Short Talk: Structural Studies and Optimization of CAR Hinge Regions
Christina Liem,
University of California, San Diego, USA
Short Talk: Mallosteric Control of the Sterol Pathway by GGPP, a Natural Monovalent Degrader
Short Talk: Mallosteric Control of the Sterol Pathway by GGPP, a Natural Monovalent Degrader
Mikolaj Slabicki,
Dana-Farber Cancer Institute, USA
Short Talk: The Human E3 Ligase RNF185 is a Regulator of the SARS-CoV-2 Envelope Protein
Short Talk: The Human E3 Ligase RNF185 is a Regulator of the SARS-CoV-2 Envelope Protein
17:00—18:45
Methodologies and Technologies for the Investigation of Protein Degradation
*
Georg E. Winter,
CeMM Research Center for Molecular Medicine, Austria
Rajesh Chopra,
Apple Tree Partners, USA
Phenotypic Screens for Identifying Modulators of E3 Ligase Function
Phenotypic Screens for Identifying Modulators of E3 Ligase Function
Christian Dillon,
PhoreMost Ltd., UK
Discovery of Novel Degraders for TPD Applications Utilising PROTEINi®-based Functional Screening
Discovery of Novel Degraders for TPD Applications Utilising PROTEINi®-based Functional Screening
Yuehan Feng,
Biognosys AG, Switzerland
Expanding the Mass Spectrometry-based Proteomics Toolbox for TPD Development from Early Discovery to the Clinics
Expanding the Mass Spectrometry-based Proteomics Toolbox for TPD Development from Early Discovery to the Clinics
Kirill Bersuker,
Calico, USA
Short Talk: PROTAC-induced Degradation of Plasma Membrane Proteins is Mediated by the Endolysosomal System
Short Talk: PROTAC-induced Degradation of Plasma Membrane Proteins is Mediated by the Endolysosomal System
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
We gratefully acknowledge additional support for this conference from:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |